- Home
- AZ vs ACIU Comparison
AZ vs ACIU Comparison
Compare AZ & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZ | ACIU |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.1M | 288.0M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AZ | ACIU |
|---|---|---|
| Price | $5.90 | $2.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $15.00 | $10.00 |
| AVG Volume (30 Days) | ★ 391.0K | 262.2K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $532.60 | $706.75 |
| Revenue Next Year | $178.94 | $321.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.00 | $1.60 |
| 52 Week High | $12.36 | $4.00 |
Technical Indicators
Market Signals| Indicator | AZ | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 37.08 | 43.93 |
| Support Level | $5.09 | $2.80 |
| Resistance Level | $6.93 | $3.13 |
| Average True Range (ATR) | 0.61 | 0.17 |
| MACD | -0.15 | -0.02 |
| Stochastic Oscillator | 31.03 | 31.00 |
Price Performance
Historical ComparisonAbout AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About ACIU AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.